-
公开(公告)号：US20180141998A1
公开(公告)日：2018-05-24
申请号：US15568487
申请日：2016-04-25
IPC分类号： C07K16/00 , G06F19/18 , A61K39/00 , A61K35/17 , C07K16/30 , C07K16/32 , G06F19/22 , A61K45/00 , A61K38/17 , A61P35/00 , C40B50/02 , G06F19/12 , C07K14/735 , A61K39/395
CPC分类号： C07K16/005 , A61K35/17 , A61K38/1774 , A61K39/0011 , A61K39/39558 , A61K45/05 , A61K2039/505 , A61K2039/55 , A61K2039/585 , A61P35/00 , C07K14/70535 , C07K16/30 , C07K16/32 , C07K2317/32 , C07K2317/34 , C07K2317/622 , C07K2317/92 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G16B5/00 , G16B20/00 , G16B30/00 , G16B35/00 , G16C20/60
摘要： Contemplated compositions and methods are directed to cancer neoepitopes and uses of such neoepitopes, especially to generate synthetic antibodies against neoepitopes that may then be employed in the manufacture of a therapeutic agent. Preferred therapeutic agents will comprise a synthetic antibody against a neoepitope, and most preferably in combination with a cellular or non-cellular component for use as a diagnostic or therapeutic agent.
-
公开(公告)号：US20220403007A1
公开(公告)日：2022-12-22
申请号：US17843247
申请日：2022-06-17
IPC分类号： C07K16/00 , G16B5/00 , G16B20/00 , G16B30/00 , G16B35/00 , G16C20/60 , A61K35/17 , C07K16/30 , C07K16/32 , C12Q1/6886 , G16B20/30 , G16B20/20 , G16B35/20 , G16B20/50 , A61P35/00 , A61K38/17 , A61K39/00 , A61K39/395 , A61K45/00 , C07K14/735
摘要： Contemplated compositions and methods are directed to cancer neoepitopes and uses of such neoepitopes, especially to generate synthetic antibodies against neoepitopes that may then be employed in the manufacture of a therapeutic agent. Preferred therapeutic agents will comprise a synthetic antibody against a neoepitope, and most preferably in combination with a cellular or non-cellular component for use as a diagnostic or therapeutic agent.
-
公开(公告)号：US11421016B2
公开(公告)日：2022-08-23
申请号：US15568487
申请日：2016-04-25
IPC分类号： C07K16/00 , G16B5/00 , G16B20/00 , G16B30/00 , G16B35/00 , G16C20/60 , A61K35/17 , C07K16/30 , C07K16/32 , C12Q1/6886 , G16B20/30 , G16B20/20 , G16B35/20 , G16B20/50 , A61P35/00 , A61K38/17 , A61K39/00 , A61K39/395 , A61K45/00 , C07K14/735
摘要： Contemplated compositions and methods are directed to cancer neoepitopes and uses of such neoepitopes, especially to generate synthetic antibodies against neoepitopes that may then be employed in the manufacture of a therapeutic agent. Preferred therapeutic agents will comprise a synthetic antibody against a neoepitope, and most preferably in combination with a cellular or non-cellular component for use as a diagnostic or therapeutic agent.
-
公开(公告)号：US11361841B2
公开(公告)日：2022-06-14
申请号：US16073105
申请日：2017-02-10
发明人： Andrew Nguyen , John Zachary Sanborn , Stephen Charles Benz , Kayvan Niazi , Shahrooz Rabizadeh , Patrick Soon-Shiong , Charles Joseph Vaske
IPC分类号： G16B20/20 , G16B20/00 , A61K35/17 , A61K39/395 , A61K48/00 , C12Q1/6886 , A61K47/68 , A61K39/00 , A61K45/06
摘要： Systems and methods are presented that allow for selection of tumor neoepitopes that are filtered for various criteria. In particularly contemplated aspects, filtering includes a step in which the mutation leading to the neoepitope is ascertained as being located in a cancer driver gene.
-
公开(公告)号：US20220165353A1
公开(公告)日：2022-05-26
申请号：US17591907
申请日：2022-02-03
发明人： Andrew Nguyen , John Zachary Sanborn , Charles Joseph Vaske , Shahrooz Rabizadeh , Kayvan Niazi , Patrick Soon-Shiong , Stephen Charles Benz
摘要： Methods for targeting a tumor antigen for immunotherapy based on HLA allele type and the mutations present in the tumor antigen are presented. A patient's HLA allele type and a tumor antigen derived from a mutation in cancer driver gene can be matched with a majority allele type having a minimum affinity to the same tumor antigen or with those of a plurality of patients with a history of cancer treatment. Upon matching, a cancer treatment against the tumor antigen can be selected and administered to the patient to achieve a desired effect.
-
公开(公告)号：US11276479B2
公开(公告)日：2022-03-15
申请号：US16465997
申请日：2017-11-30
发明人： Andrew Nguyen , John Zachary Sanborn , Charles Joseph Vaske , Shahrooz Rabizadeh , Kayvan Niazi , Patrick Soon-Shiong , Stephen Charles Benz
摘要： Methods for targeting a tumor antigen for immunotherapy based on HLA allele type and the mutations present in the tumor antigen are presented. A patient's HLA allele type and a tumor antigen derived from a mutation in cancer driver gene can be matched with a majority allele type having a minimum affinity to the same tumor antigen or with those of a plurality of patients with a history of cancer treatment. Upon matching, a cancer treatment against the tumor antigen can be selected and administered to the patient to achieve a desired effect.
-
公开(公告)号：US11154597B2
公开(公告)日：2021-10-26
申请号：US15468046
申请日：2017-03-23
IPC分类号： A61K39/00 , A61K39/39 , C07K7/06 , C07K14/74 , C07K14/705 , C12N7/00 , C12N15/86 , G16B20/00 , G16B20/20
摘要： Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate a recombinant polytope that is optimized for proper trafficking and processing. In preferred methods, the polytope is encoded in a viral expression system that is used as a therapeutic agent.
-
8.发明申请公开(公告)号：US20190034582A1
公开(公告)日：2019-01-31
申请号：US16073105
申请日：2017-02-10
发明人： Andrew Nguyen , John Zachary Sanborn , Steven Charles Benz , Kayvan Niazi , Shahrooz Rabizadeh , Patrick Soon-Shiong , Charles Joseph Vaske
摘要： Systems and methods are presented that allow for selection of tumor neoepitopes that are filtered for various criteria. In particularly contemplated aspects, filtering includes a step in which the mutation leading to the neoepitope is ascertained as being located in a cancer driver gene.
-
公开(公告)号：US20200297830A1
公开(公告)日：2020-09-24
申请号：US16874104
申请日：2020-05-14
申请人： NantCell , Nant Holdings IP, LLC , Nantomics
摘要： Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate a recombinant polytope that is optimized for proper trafficking and processing. In preferred methods, the polytope is encoded in a viral expression system that is used as a therapeutic agent.
-
公开(公告)号：US20170312351A1
公开(公告)日：2017-11-02
申请号：US15468046
申请日：2017-03-23
IPC分类号： A61K39/00 , C12N7/00 , C12N15/86 , G06F19/18 , A61K39/39 , C07K14/74 , C07K14/705 , C07K7/06
CPC分类号： A61K39/0011 , A61K39/39 , A61K2039/5254 , A61K2039/5256 , A61K2039/57 , A61K2039/572 , A61K2039/70 , C07K7/06 , C07K14/70539 , C07K14/70596 , C07K2319/01 , C07K2319/06 , C07K2319/40 , C07K2319/95 , C12N7/00 , C12N15/86 , C12N2710/10321 , C12N2710/10334 , C12N2710/10343 , C12N2840/002 , G16B20/00
摘要： Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate a recombinant polytope that is optimized for proper trafficking and processing. In preferred methods, the polytope is encoded in a viral expression system that is used as a therapeutic agent.
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.023 秒)
